A PHASE IA/B, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS
2019-004596-39CANCERES LOCALMENTE AVANZADOS O METASTASICOSFundación Jiménez DíazInvestigador: MORENO GARCIA VICTOR
